title: Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
abstract: Brentuximab vedotin (BV) is a monoclonal antibody-drug conjugate that targets CD30, and has been reported to be effective for relapsed/refractory anaplastic large cell lymphoma. We here report a patient who experienced multiple relapses after conventional chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). He achieved a complete metabolic response with BV and proceeded to undergo haploidentical HSCT. After HSCT, he received three doses of BV to prevent an early relapse, and remains in remission 16 months post-transplantation. Our case suggests the potential use of BV both as a bridging therapy to allogeneic HSCT and as a maintenance therapy post-transplantation.
authors: Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
authors: Kyung-Nam
authors: KN
authors: Koh
authors: Ho Joon
authors: HJ
authors: Im
authors: Jin Kyung
authors: JK
authors: Suh
authors: Seong Wook
authors: SW
authors: Lee
authors: Eun Seok
authors: ES
authors: Choi
authors: Jong Jin
authors: JJ
authors: Seo
mesh_terms: D000293:Adolescent; D000079963:Brentuximab Vedotin; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000401:mortality / Q000628:therapy*; D008297:Male; D014184:Transplantation, Homologous
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: allogeneic hematopoietic stem cell transplantation; anaplastic large cell lymphoma; brentuximab vedotin; haploidentical